These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29968849)

  • 1. Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R.
    Liu YQ; Wang YN; Lu XY; Tong LJ; Li Y; Zhang T; Xun QJ; Feng F; Chen YZ; Su Y; Shen YY; Chen Y; Geng MY; Ding K; Li YL; Xie H; Ding J
    Acta Pharmacol Sin; 2018 Nov; 39(11):1768-1776. PubMed ID: 29968849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The c.1085A>G Genetic Variant of
    Yeh YM; Hsu SJ; Lin PC; Hsu KF; Wu PY; Su WC; Chang JY; Shen MR
    Clin Cancer Res; 2017 Oct; 23(20):6021-6030. PubMed ID: 28724665
    [No Abstract]   [Full Text] [Related]  

  • 3. Discovery of Pyrrolo[2,3-d]pyrimidine derivatives as potent and selective colony stimulating factor 1 receptor kinase inhibitors.
    Liang X; Wang C; Wang B; Liu J; Qi S; Wang A; Liu Q; Deng M; Wang L; Liu J; Liu Q
    Eur J Med Chem; 2022 Dec; 243():114782. PubMed ID: 36179404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency.
    Zhou Y; Shan S; Li ZB; Xin LJ; Pan DS; Yang QJ; Liu YP; Yue XP; Liu XR; Gao JZ; Zhang JW; Ning ZQ; Lu XP
    Cancer Sci; 2017 Mar; 108(3):469-477. PubMed ID: 28004478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability.
    Murga-Zamalloa C; Rolland DCM; Polk A; Wolfe A; Dewar H; Chowdhury P; Onder O; Dewar R; Brown NA; Bailey NG; Inamdar K; Lim MS; Elenitoba-Johnson KSJ; Wilcox RA
    Clin Cancer Res; 2020 Feb; 26(3):690-703. PubMed ID: 31636099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Properties of JTE-952, an Orally Available and Selective Colony Stimulating Factor 1 Receptor Kinase Inhibitor.
    Uesato N; Miyagawa N; Inagaki K; Kakefuda R; Kitagawa Y; Matsuo Y; Yamaguchi T; Hata T; Ikegashira K; Matsushita M
    Biol Pharm Bull; 2020; 43(2):325-333. PubMed ID: 32009119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.
    Ramesh A; Brouillard A; Kumar S; Nandi D; Kulkarni A
    Biomaterials; 2020 Jan; 227():119559. PubMed ID: 31670078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of potent colony-stimulating factor 1 receptor inhibitors by replacement of hinge-binder moieties.
    Lee JW; Park J; Kim J; Kim J; Choi C; Min KH
    Eur J Med Chem; 2021 Apr; 216():113298. PubMed ID: 33689933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, Synthesis, and Structure-Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5- d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors.
    Xun Q; Zhang Z; Luo J; Tong L; Huang M; Wang Z; Zou J; Liu Y; Xu Y; Xie H; Tu ZC; Lu X; Ding K
    J Med Chem; 2018 Mar; 61(6):2353-2371. PubMed ID: 29499108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias.
    Bourrié B; Brassard DL; Cosnier-Pucheu S; Zilberstein A; Yu K; Levit M; Morrison JG; Perreaut P; Jegham S; Hilairet S; Bouaboula M; Penarier G; Guiot C; Larroze-Chicot P; Laurent G; Demur C; Casellas P
    Leuk Lymphoma; 2013 Jul; 54(7):1488-99. PubMed ID: 23121564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
    Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
    J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
    Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
    J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.
    Joshi KS; Rathos MJ; Mahajan P; Wagh V; Shenoy S; Bhatia D; Chile S; Sivakumar M; Maier A; Fiebig HH; Sharma S
    Mol Cancer Ther; 2007 Mar; 6(3):926-34. PubMed ID: 17363487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.
    Edwards DK; Watanabe-Smith K; Rofelty A; Damnernsawad A; Laderas T; Lamble A; Lind EF; Kaempf A; Mori M; Rosenberg M; d'Almeida A; Long N; Agarwal A; Sweeney DT; Loriaux M; McWeeney SK; Tyner JW
    Blood; 2019 Feb; 133(6):588-599. PubMed ID: 30425048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment.
    O'Brien SA; Orf J; Skrzypczynska KM; Tan H; Kim J; DeVoss J; Belmontes B; Egen JG
    Cancer Immunol Immunother; 2021 Aug; 70(8):2401-2410. PubMed ID: 33511454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF1R signaling is a regulator of pathogenesis in progressive MS.
    Hagan N; Kane JL; Grover D; Woodworth L; Madore C; Saleh J; Sancho J; Liu J; Li Y; Proto J; Zelic M; Mahan A; Kothe M; Scholte AA; Fitzgerald M; Gisevius B; Haghikia A; Butovsky O; Ofengeim D
    Cell Death Dis; 2020 Oct; 11(10):904. PubMed ID: 33097690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma.
    Wang Q; Lu Y; Li R; Jiang Y; Zheng Y; Qian J; Bi E; Zheng C; Hou J; Wang S; Yi Q
    Leukemia; 2018 Jan; 32(1):176-183. PubMed ID: 28626216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
    Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
    Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
    [No Abstract]   [Full Text] [Related]  

  • 20. Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes.
    Webb MW; Sun J; Sheard MA; Liu WY; Wu HW; Jackson JR; Malvar J; Sposto R; Daniel D; Seeger RC
    Int J Cancer; 2018 Sep; 143(6):1483-1493. PubMed ID: 29665011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.